HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men

West of Scotland Coronary Prevention Study

^a Departments of Medical Cardiology, Medicine and Pathological Biochemistry and Statistics, University of Glasgow, Royal Infirmary, Glasgow, United Kingdom

View larger version (16K): [in a new window]   Figure 1 Kaplan-Meier plots of time to first hospitalization by treatment group for (a) cardiovascular and (b) noncardiovascular trial categories. Log-rank p-values are given for the test of equality of survival curves between the treatment groups.

View larger version (18K): [in a new window]   Figure 2 Effect of pravastatin on noncardiovascular hospital admissions by ICD 8 Body System Code. The point estimate is indicated by a diamond for the difference between placebo and pravastatin groups in the mean number of admissions/1,000 subject-years. Negative values indicate reduction in hospitalization in pravastatin-treated subjects. Approximate 95% CIs with permutation p-value are indicated.

View larger version (37K): [in a new window]   Figure 3 Hospital admissions by treatment group for (A) cardiovascular and (B) noncardiovascular trial categories by quartiles of baseline 5-year untreated risk of definite CHD death or nonfatal MI. See text for details.